NAVIGATE 24-Month Results: Electromagnetic Navigation Bronchoscopy for Pulmonary Lesions at 37 Centers in Europe and the United States.


Journal

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
ISSN: 1556-1380
Titre abrégé: J Thorac Oncol
Pays: United States
ID NLM: 101274235

Informations de publication

Date de publication:
04 2022
Historique:
received: 12 03 2021
revised: 23 11 2021
accepted: 10 12 2021
pubmed: 2 1 2022
medline: 30 4 2022
entrez: 1 1 2022
Statut: ppublish

Résumé

Electromagnetic navigation bronchoscopy (ENB) is a minimally invasive, image-guided approach to access lung lesions for biopsy or localization for treatment. However, no studies have reported prospective 24-month follow-up from a large, multinational, generalizable cohort. This study evaluated ENB safety, diagnostic yield, and usage patterns in an unrestricted, real-world observational design. The NAVIGATE single-arm, pragmatic cohort study (NCT02410837) enrolled subjects at 37 academic and community sites in seven countries with prospective 24-month follow-up. Subjects underwent ENB using the superDimension navigation system versions 6.3 to 7.1. The prespecified primary end point was procedure-related pneumothorax requiring intervention or hospitalization. A total of 1388 subjects were enrolled for lung lesion biopsy (1329; 95.7%), fiducial marker placement (272; 19.6%), dye marking (23; 1.7%), or lymph node biopsy (36; 2.6%). Concurrent endobronchial ultrasound-guided staging occurred in 456 subjects. General anesthesia (78.2% overall, 56.6% Europe, 81.4% United States), radial endobronchial ultrasound (50.6%, 4.0%, 57.4%), fluoroscopy (85.0%, 41.7%, 91.0%), and rapid on-site evaluation use (61.7%, 17.3%, 68.5%) differed between regions. Pneumothorax and bronchopulmonary hemorrhage occurred in 4.7% and 2.7% of subjects, respectively (3.2% [primary end point] and 1.7% requiring intervention or hospitalization). Respiratory failure occurred in 0.6%. The diagnostic yield was 67.8% (range: 61.9%-70.7%; 55.2% Europe, 69.8% United States). Sensitivity for malignancy was 62.6%. Lung cancer clinical stage was I to II in 64.7% (55.3% Europe, 65.8% United States). Despite a heterogeneous cohort and regional differences in procedural techniques, ENB demonstrates low complications and a 67.8% diagnostic yield while allowing biopsy, staging, fiducial placement, and dye marking in a single procedure.

Identifiants

pubmed: 34973418
pii: S1556-0864(21)03414-6
doi: 10.1016/j.jtho.2021.12.008
pii:
doi:

Types de publication

Journal Article Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

519-531

Informations de copyright

Copyright © 2021. Published by Elsevier Inc.

Auteurs

Erik E Folch (EE)

Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. Electronic address: efolch@mgh.harvard.edu.

Mark R Bowling (MR)

Division of Pulmonary Critical Care and Sleep Medicine, Brody School of Medicine, East Carolina University, Greenville, North Carolina.

Michael A Pritchett (MA)

Pulmonary and Critical Care Medicine, FirstHealth of the Carolinas and Pinehurst Medical Clinic, Pinehurst, North Carolina.

Septimiu D Murgu (SD)

Section of Pulmonary and Critical Care Medicine/Interventional Pulmonology, University of Chicago Medicine, Chicago, Illinois.

Michael A Nead (MA)

Pulmonary and Critical Care Medicine, University of Rochester Medical Center, Rochester, New York.

Javier Flandes (J)

Bronchoscopy and Interventional Unit, Hospital Fundación Jiménez Díaz IIS-FJD Ciberes, Madrid, Spain.

William S Krimsky (WS)

Gala Therapeutics, San Carlos, CA.

Amit K Mahajan (AK)

Interventional Pulmonology and Complex Airways Disease Program, Division of Thoracic Surgery, Virginia Cancer Specialists, Inova Health System, Falls Church, Virginia.

Gregory P LeMense (GP)

Pulmonary and Sleep Medicine, Blount Memorial Physicians Group, Alcoa, Tennessee; Present Address: Pulmonary Medicine, Bozeman Health, Bozeman, Montana.

Boris A Murillo (BA)

Ascension Medical Group Providence Lung Clinic, Providence Health Center and Waco Lung Associates, Waco, Texas.

Sandeep Bansal (S)

Interventional Pulmonology, Penn Highlands Healthcare, DuBois, Pennsylvania.

Kelvin Lau (K)

Cardiothoracic Surgery, St. Bartholomew's Hospital, West Smithfield, London, United Kingdom.

Thomas R Gildea (TR)

Department of Pulmonary, Allergy, and Critical Care Medicine and Transplant Center, Cleveland Clinic, Cleveland, Ohio.

Merete Christensen (M)

Department of Cardiothoracic Surgery, Rigshospitalet, Thoraxkirurgisk klin, Copenhagen, Denmark.

Douglas A Arenberg (DA)

Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, Michigan.

Jaspal Singh (J)

Pulmonary, Critical Care, and Sleep Medicine, Carolinas Medical Center, Atrium Health and Levine Cancer Institute, Charlotte, North Carolina.

Krish Bhadra (K)

Interventional Pulmonology, CHI Memorial Rees Skillern Cancer Institute, Chattanooga, Tennessee.

D Kyle Hogarth (DK)

Section of Pulmonary and Critical Care Medicine/Interventional Pulmonology, The University of Chicago Medicine, Chicago, Illinois.

Christopher W Towe (CW)

Division of Thoracic and Esophageal Surgery, Department of Surgery, University Hospitals Cleveland Medical Center, Cleveland, Ohio.

Bernd Lamprecht (B)

Klinik für Lungenheilkunde, Kepler Universitätsklinikum GmbH, Linz, Austria.

Michela Bezzi (M)

Azienda Ospedaliero Universitaria Careggi, Florence, Italy.

Jennifer S Mattingley (JS)

Pulmonary and Critical Care, Gundersen Health System, La Crosse, Wisconsin; Present Address: Clinical Research and Medical Science, Medtronic, Plymouth, Minnesota.

Kristin L Hood (KL)

Clinical Research and Medical Science, Medtronic, Plymouth, Minnesota.

Haiying Lin (H)

Clinical Research and Medical Science, Medtronic, Plymouth, Minnesota.

Jennifer J Wolvers (JJ)

Clinical Research and Medical Science, Medtronic, Plymouth, Minnesota.

Sandeep J Khandhar (SJ)

Division of Thoracic Surgery, Virginia Cancer Specialists, Inova Health System, Fairfax, Virginia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH